GlassScriptPhysician profile
Allison L Scanlon
NPI 1356395461
$2,982.37
in general payments reported to CMS, 2019-2025
25 companies · $507 in 2025
The $507 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $436 · 2022: $911 · 2023: $597 · 2024: $532 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $888.71 | 2021-2025 | General - Pain Management, Varithena Administration Pack, Wavewriter Alpha Prime 16 |
| Forte Bio-Pharma LLC | $256.72 | 2024 | Prolate, Nalocet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.64 | 2021-2025 | Relistor |
| Ucb, INC. | $244.72 | 2021-2022 | |
| Nevro Corp. | $186.29 | 2022 | |
| Medtronic, INC. | $178.92 | 2022 | |
| Abbott Laboratories | $129.26 | 2022 | |
| Grt US Holding, INC. | $124.80 | 2022 | |
| Relievant Medsystems, INC. | $106.67 | 2022 | |
| Foundation Fusion Solutions, LLC | $106.27 | 2024-2025 | |
| Stimwave Technologies Incorporated | $100.62 | 2021 | |
| Saluda Medical Americas, INC. | $84.74 | 2025 | Evoke |
| Averitas Pharma INC. | $71.25 | 2023-2025 | Qutenza |
| Collegium Pharmaceutical, INC. | $31.98 | 2023 | Belbuca, Xtampza |
| Biotronik Nro, INC. | $30.47 | 2024-2025 | Prospera |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $26.68 | 2021 | |
| Scilex Pharmaceuticals INC. | $23.52 | 2023 | Ztlido |
| Trevena, INC. | $23.28 | 2021 | |
| Merck Sharp & Dohme LLC | $22.80 | 2023 | Gardasil 9 |
| Pacira Pharmaceuticals Incorporated | $22.52 | 2025 | Iovera, Zilretta |
| Tersera Therapeutics LLC | $20.41 | 2022 | |
| Valinor Pharma, LLC | $17.01 | 2025 | Movantik |
| Virtus Pharmaceuticals LLC | $13.84 | 2021 | |
| Curonix LLC | $13.14 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Redhill Biopharma INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Scanlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.